insights_auto
Why is BAVA up 2,54%?
Dive Deeperchevron_right
BAVA:VIE
Bavarian Nordic A/S
€31,50
arrow_upward
+2,54%(+0,78) 1D
9 Okt., 17:36:00 GMT+2 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BAVA...
Open
€31,02
High
€31,64
Low
€31,02
Mkt. cap
2,82Â mjd
Avg. vol.
17,00
Volume
0,00
52-wk high
€32,47
52-wk low
€22,96
No. of employees
2Â k
Open
€31,02
High
€31,64
Low
€31,02
Mkt. cap
2,82Â mjd
Avg. vol.
17,00
Volume
0,00
52-wk high
€32,47
52-wk low
€22,96
No. of employees
2Â k
News stories
From web sources and news partners
Seeking Alpha
·
32 minute gelede
15 Years In, I've Never Seen The S&P 500 Hide So Much Damage
Simply Wall Street
·
1 uur gelede
Low Valuation Could Change The Case For APA Stock (APA)
Forbes
·
1 uur gelede
Stock Market Crash Hits 54% Of Stocks—Is The S&P 500 Next?
Profile
Bavarian Nordic A/S is a Danish biotechnology company focused on the development, manufacturing and commercialization of vaccines. The company is headquartered in Hellerup, Denmark, with manufacturing facilities in Kvistgård, Denmark and Thörishaus near Bern, Switzerland. The company has research and development facilities in Martinsried, Germany, as well as offices in USA, Canada, and France. The company uses viral vectors and virus-like particles in its research and development.
In July 2025, the company agreed to be acquired by private equity firms Permira and Nordic Capital for 19 billion kr. However, in November, the acquisition failed to gain sufficient support from Bavarian Nordic's shareholders, leading to its termination.
In 2026, Bavarian Nordic was ranked second in Time Magazine's World Most Impactful Companies. Wikipedia
About Bavarian Nordic A/S